ATE363074T1 - Substrate und screeningverfahren für transportproteine - Google Patents

Substrate und screeningverfahren für transportproteine

Info

Publication number
ATE363074T1
ATE363074T1 AT00966735T AT00966735T ATE363074T1 AT E363074 T1 ATE363074 T1 AT E363074T1 AT 00966735 T AT00966735 T AT 00966735T AT 00966735 T AT00966735 T AT 00966735T AT E363074 T1 ATE363074 T1 AT E363074T1
Authority
AT
Austria
Prior art keywords
transport proteins
substrates
screening methods
methods
screening
Prior art date
Application number
AT00966735T
Other languages
English (en)
Inventor
William Dower
Mark Gallop
Ronald Barrett
Kenneth Cundy
Tania Chernov-Rogan
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE363074T1 publication Critical patent/ATE363074T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/081,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1086Preparation or screening of expression libraries, e.g. reporter assays
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00Systems containing at least three condensed rings
    • C07C2603/02Ortho- or ortho- and peri-condensed systems
    • C07C2603/04Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18Fluorenes; Hydrogenated fluorenes
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
AT00966735T 1999-09-14 2000-09-14 Substrate und screeningverfahren für transportproteine ATE363074T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15407199P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ATE363074T1 true ATE363074T1 (de) 2007-06-15

Family

ID=22549879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966735T ATE363074T1 (de) 1999-09-14 2000-09-14 Substrate und screeningverfahren für transportproteine

Country Status (6)

Country Link
US (2) US7413536B1 (de)
EP (1) EP1212619B1 (de)
AT (1) ATE363074T1 (de)
AU (1) AU7703400A (de)
DE (1) DE60034954D1 (de)
WO (1) WO2001020331A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1267898A4 (de) * 2000-04-07 2006-02-01 Univ Maryland Gallensäure enthaltend propharmaka mit erhöhter bioavibilität
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
EP2067784A3 (de) 2000-08-05 2012-08-22 Glaxo Group Limited 17.beta.-Carbothioat-17.alpha.-Arylcarbonyloxyloxy-Androstan-Derivate als entzündungshemmende Mittel
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
EP1361847A2 (de) 2000-10-06 2003-11-19 Xenoport, Inc. Gallensäurekonjugate zur bereitstellung anhaltender systemischer arneimittelkonzentrationen
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
WO2002088167A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
JP4342934B2 (ja) 2001-06-11 2009-10-14 キセノポート インコーポレーティッド Pept−2輸送体を介した薬剤の投与
US7420002B2 (en) 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7026166B2 (en) * 2002-01-22 2006-04-11 Chiron Corporation Fluorogenic dyes
WO2003070174A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
FR2840407B1 (fr) * 2002-05-31 2008-07-18 Commissariat Energie Atomique Methode de criblage de banques de biomolecules et ses applications
CA2486911A1 (fr) 2002-05-31 2003-12-11 Commissariat A L'energie Atomique Methode de criblage de banques de molecules radioactives et ses applications
FR2840994B1 (fr) * 2003-01-22 2008-07-18 Commissariat Energie Atomique Methode de criblage de banques de biomolecules et ses applications
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040161424A1 (en) * 2002-10-08 2004-08-19 Xenoport Human organic solute transporters
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US7704756B2 (en) 2003-01-21 2010-04-27 Novartis Vaccines And Diagnostics, Inc. Fluorogenic dyes
WO2005075992A1 (en) * 2004-01-30 2005-08-18 Xenoport, Inc. Mct1 transporter expressed in blood brain barrier cells
UA88008C2 (en) * 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
PT1781596E (pt) 2004-07-12 2009-01-12 Xenoport Inc Pró-fármacos de propofol derivados de aminoácidos, composições e utilizações dos mesmos
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
WO2007038659A1 (en) * 2005-09-26 2007-04-05 Invitrogen Corporation Violet laser excitable dyes and their method of use
US20090184006A1 (en) * 2006-01-31 2009-07-23 Sanofi-Aventis Method for the determination of the activity of the organic cation transporter
EP1991702A4 (de) * 2006-02-17 2009-04-22 Univ Leland Stanford Junior Sequenzielle reportergen-lumineszenz (srl)-verfahren und zusammensetzung zu ihrer ausführung
CN101421411B (zh) 2006-04-13 2015-06-03 中外制药株式会社 牛磺酸转运蛋白基因
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
WO2008114673A1 (ja) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha ポリペプチドの製造方法
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
WO2009051109A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
AU2008314973C1 (en) 2007-10-24 2014-05-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
WO2009129305A2 (en) 2008-04-15 2009-10-22 Tsrl, Inc. Prodrugs of neuraminidase inhibitors
US20120004137A1 (en) * 2009-02-13 2012-01-05 X-Body, Inc. Identification of nucleic acid delivery vehicles using dna display
KR102231531B1 (ko) 2009-02-13 2021-03-23 엑스-켐, 인크. Dna―코딩된 라이브러리의 생성 및 스크리닝 방법
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
WO2011008912A1 (en) * 2009-07-16 2011-01-20 Beckman Coulter, Inc. Novel fluorescent dyes and uses thereof
JP5561692B2 (ja) * 2010-03-09 2014-07-30 国立大学法人群馬大学 新規蛍光化合物およびそれを用いた細胞内コレステロールの検出方法
EP3593802A3 (de) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
US8399262B2 (en) 2011-03-23 2013-03-19 Darrel A. Mazzari Biosensor
ES2675111T3 (es) 2011-09-07 2018-07-06 X-Chem, Inc. Métodos para etiquetar bibliotecas con codificación de ADN
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
CN104685115A (zh) 2012-07-13 2015-06-03 X-化学有限公司 具有聚合酶不可读的编码性寡核苷酸连接的dna编码文库
KR20160003664A (ko) 2013-03-15 2016-01-11 루메나 파마수티컬즈, 인코포레이티드 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
EP2968230A2 (de) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von primär sklerosierender cholongitis und entzündlichen darmerkrankungen
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
CA3007635A1 (en) 2015-12-07 2017-06-15 Zymergen Inc. Promoters from corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
WO2018005793A1 (en) * 2016-06-30 2018-01-04 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
JP2019519242A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド 細菌ヘモグロビンライブラリーを生成するための方法およびその使用
GB2552460A (en) * 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
CA3129826A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
WO2021081404A1 (en) 2019-10-25 2021-04-29 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5569678A (en) 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5866123A (en) 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US5236902A (en) 1990-11-26 1993-08-17 The Governors Of The University Of Alberta Method and probes for detecting nucleoside transporter and method for producing the probes
US5580775A (en) 1992-05-01 1996-12-03 Emory University High affinity, brain-specific nucleic acids encoding a L-proline transporter, and vectors, and host cells comprising the same
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
DE4222315A1 (de) 1992-07-05 1994-01-13 Inst Genbiologische Forschung DNA-Sequenzen für Aminosäuretransporter, Plasmide, Bakterien, Hefen und Pflanzen enthaltend einen Transporter
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5658782A (en) 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
DE4343527A1 (de) 1993-12-16 1995-06-22 Schering Ag Verfahren zur Identifizierung von Stoffen mit potentieller herbizider oder wachstumsregulatorischer Wirkung mittels pflanzlicher Transporterproteine, Verwendung der Transporterproteine sowie Substanzen mit herbizider und wachstumsregulatorischer Wirkung
US5589358A (en) * 1993-12-29 1996-12-31 Univ Wake Forest Ileal bile acid transporter compositions and methods
US5849525A (en) 1994-03-09 1998-12-15 Brigham And Women's Hospital, Inc. Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same
EP0790976B1 (de) * 1994-11-12 1999-04-21 Basf Aktiengesellschaft Verfahren zur herstellung von aminen aus verbindungen mit mindestens 3 cyanogruppen
WO1996034112A1 (en) * 1995-04-24 1996-10-31 Chromaxome Corp. Methods for generating and screening novel metabolic pathways
EP0773441B1 (de) 1995-09-11 2000-08-02 La Jolla Cancer Research Foundation Moleküle, die sich in ausgewählten Organen oder Geweben invivo Einfinden und Verfahren zu ihrer Identifizierung
EP1281718A3 (de) 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptiden die den Transport über Geweben erhöhen
US5780264A (en) 1996-06-06 1998-07-14 The President And Fellows Of Harvard College Iron transport protein
EP0923603A1 (de) 1996-07-16 1999-06-23 Novo Nordisk A/S Oligopeptid-transporter
US6361938B1 (en) 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
WO1998038490A1 (en) 1997-02-27 1998-09-03 Cellomics, Inc. A system for cell-based screening
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
AU755154B2 (en) * 1997-05-15 2002-12-05 Cytogen Corporation Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
EP1001927A2 (de) * 1997-07-15 2000-05-24 Oridigm Corporation Polyamine analoge als arzneimittel und diagnostikum

Also Published As

Publication number Publication date
EP1212619B1 (de) 2007-05-23
WO2001020331A9 (en) 2002-10-03
US20090221442A1 (en) 2009-09-03
AU7703400A (en) 2001-04-17
EP1212619A4 (de) 2004-12-08
US7413536B1 (en) 2008-08-19
DE60034954D1 (de) 2007-07-05
EP1212619A1 (de) 2002-06-12
WO2001020331A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
DE60034954D1 (de) Substrate und screeningverfahren für transportproteine
NO20043245L (no) Bindingsproteiner som biosensorer
NO20043259L (no) Bindingsproteiner som biosensorer
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
ATE295347T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
DE60137203D1 (de) Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
DE60005787D1 (de) Wasserlösliche rhodaminfarbstoffe und ihre konjugate
NO20043257L (no) Innkapslede bindingsproteiner som biosensorer
ATE233762T1 (de) Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung
DE69739856D1 (de) Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
ATE294164T1 (de) Fluoreszenzfarbstoffe zum festphasen- und flüssigphasen-screening
ATE352784T1 (de) Verfahren zum screenen für gpr40-liganden
ITRM980303A0 (it) Composizione contenente radioisotopi immobilizzati su particelle solide utile in particolare per la biancheria clinica in patologie
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
DE59806371D1 (de) Kontrastmittel für das infarkt- und nekroseimaging
DE69912839D1 (de) Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung
GB0208989D0 (en) Methods for measuring enzyme activity
WO1999050459A3 (en) High throughput in vitro screening assays for transcription modulators
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
MXPA03001536A (es) (aminoalcoxibenzoil) benzofuranos o benzotiofenos, metodo para preparar los mismo y composiciones que los contienen.
MXPA03011898A (es) Ensayo de seleccion in vitro para ?- secretasa.
WO2001008707A3 (de) Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen
ATE252574T1 (de) Benzofuran-2-ones als färbemittel für organische materialien
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties